Brain cell injection could tame Drug-Resistant epilepsy
NCT ID NCT07572812
First seen Jun 25, 2026 · Last updated Jul 28, 2026 · Updated 3 times
Summary
This early-stage trial tests a new cell therapy called UX-GIP001 for adults with drug-resistant temporal lobe epilepsy. The treatment involves injecting special brain cells into the seizure area to calm overactive nerves. Only 12 people will take part, and the main goal is to check safety and see if seizures decrease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- UX-GIP001 (human GABAergic interneuron progenitor cells)
- What this could lead to
- If successful, this could point toward a new treatment option for people with drug-resistant epilepsy, potentially reducing or stopping seizures.
- What could go wrong
- This is a very early Phase 1 trial with only 12 participants, so safety and effectiveness are not yet proven. The cell injection into the brain carries surgical risks, and participants may need lifelong immunosuppression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 12 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2029
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-75 years (inclusive), male or female; * Diagnosis of focal epilepsy according to the International League Against Epilepsy (ILAE) 2025 epilepsy classification, with disease duration ≥2 years; * Clinical presentation consistent with unilateral mesial temporal lobe epilepsy (MTLE); * Meeting the diagnostic criteria for drug-resistant epilepsy; * Average focal seizure frequency ≥4 per 28 days within the 3 months prior to screening; * On a stable dose of anti-seizure medications for ≥1 month prior to enrollment; * Patient has adequate organ function as follows: absolute neutrophil count ≥2.0×10⁹/L; white blood cell count ≥4.0×10⁹/L; platelet count ≥100×10⁹/L; AST and ALT ≤2.5× upper limit of normal (ULN); total bilirubin ≤1.5× ULN; serum creatinine ≤1.5× ULN; estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m² (calculated using the CKD-EPI formula); * Women of childbearing potential must have a negative serum pregnancy test during the screening period. All participants and their partners agree to have no plans for pregnancy, sperm donation, or egg donation from the time of signing the informed consent form until 2 years after cell transplantation treatment, and voluntarily adopt contraceptive measures deemed effective by the investigator; * Patient has good compliance, with a patient diary completion rate ≥80% prior to enrollment. Exclusion Criteria: * Epilepsy caused by other/or progressive neurological diseases , or patients - experiencing only focal aware seizures without observable manifestations. * History of epilepsy surgery. * History of status epilepticus within 12 months prior to screening. * Presence of long-term implants in the skull or intracranial space. * Severe systemic disease or dysfunction. * Primary or secondary immunodeficiency. * History of clear suicidal intent, plan, or behavior within one year prior to screening. * Severe psychiatric disorders. * History of malignancy within the past 5 years, except for cervical carcinoma in situ, basal cell or squamous cell skin cancer cured for \>5 years. * Pregnant or breastfeeding women.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Drug-resistant unilateral mesial temporal lobe epilepsy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100070, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450000, China
-
West China School of Medicine and West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can lavender and lullabies help kids with epilepsy sleep better?
- Reading the Brain's signals to predict who benefits from deep brain stimulation
- Can a Comfort-Focused education program improve life with epilepsy?
- Can video games rewire young brains after injury?
- High-Fat Diet's effect on epilepsy: scientists track brain signals
- Epilepsy drug candidate put to the test in healthy volunteers